Article
Endocrinology & Metabolism
Odette S. Reifsnider, Pratik Pimple, Sarah Brand, Evelien Bergrath Washington, Sharash Shetty, Nihar R. Desai
Summary: The study found that for patients with type 2 diabetes, the use of empagliflozin as second-line treatment after metformin is a dominant strategy for US payers, associated with lower lifetime costs, improved quality-adjusted life years, and reductions in cardiovascular death rates and complication rates in patients with cardiovascular diseases.
DIABETES OBESITY & METABOLISM
(2022)
Article
Medicine, Research & Experimental
Hideaki Kaneto, Mike Baxter, Yoko Takahashi, Yasuo Terauchi
Summary: Japanese individuals with T2D achieved better glycemic control by simultaneous initiation of lixisenatide and BI compared to sequential initiation, with a mean change in HbA1c of -0.69% and higher treatment response rates, but also higher incidence of hypoglycemia.
ADVANCES IN THERAPY
(2022)
Article
Multidisciplinary Sciences
Kenichi Tanaka, Yosuke Okada, Akemi Tokutsu, Yoshiya Tanaka
Summary: Real-world data shows that liraglutide and dulaglutide have comparable effectiveness in lowering HbA1c levels in patients with T2DM.
SCIENTIFIC REPORTS
(2022)
Article
Public, Environmental & Occupational Health
Qiong Luo, Li Zhou, Naitong Zhou, Ming Hu
Summary: This study evaluated the long-term cost effectiveness of insulin degludec/insulin aspart (IDegAsp) vs. biphasic insulin aspart 30 (BIAsp 30) for the treatment of Chinese patients with inadequately managed type 2 diabetes mellitus (T2DM). The results showed that IDegAsp was associated with higher life years and quality-adjusted life years compared to BIAsp 30 over a 30-year time horizon. Additionally, the total costs were slightly higher with IDegAsp therapy. Therefore, IDegAsp was considered a cost-effective treatment option for people with inadequate glycemic management on basal insulin in China.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Endocrinology & Metabolism
Wenying Yang, Xiaolin Dong, Qingju Li, Zhifeng Cheng, Guoyue Yuan, Ming Liu, Jianzhong Xiao, Shenghong Gu, Elisabeth Niemoeller, Lijuan Chen, Lin Ping, Elisabeth Souhami
Summary: In Asian Pacific people with suboptimally controlled type 2 diabetes, iGlarLixi demonstrated significant reductions in HbA1c levels compared to iGlar and Lixi, with better outcomes in terms of weight management and hypoglycemia.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Lars Holger Ehlers, Mark Lamotte, Sofia Monteiro, Susanne Sandgaard, Pia Holmgaard, Evan C. Frary, Niels Ejskjaer
Summary: The study focused on assessing the cost-effectiveness of empagliflozin plus standard of care compared to liraglutide plus standard of care in Danish patients with T2D and established CVD, revealing that empagliflozin was the dominant treatment option over both lifetime and 5-year horizons.
Article
Endocrinology & Metabolism
Natalia McInnes, Stephanie A. Hall, Heather A. B. Lochnan, Stewart B. Harris, Zubin J. Punthakee, Ronald J. Sigal, Irene Hramiak, Mohammed F. Azharuddin, Joanne F. Liutkus, Jean-Francois Yale, Farah Sultan, Ada E. Smith, Rose E. Otto, Diana Sherifali, Yan Yun C. Liu, Hertzel C. Gerstein
Summary: Combining lifestyle approaches and short-term intensive glucose-lowering therapy can induce remission of type 2 diabetes. The intervention significantly reduced the risk of diabetes relapse at 24 weeks and resulted in higher rates of diabetes remission at 24 to 64 weeks compared to standard care.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Anastasia-Stefania Alexopoulos, Andreas Andersen, Anders Meller Donatsky, Amoolya Gowda, John B. Buse
Summary: In both the DEVOTE and SWITCH 2 trials, insulin degludec 100 units/mL was shown to be superior to insulin glargine 100 units/mL in reducing rates of severe hypoglycemia in individuals with type 2 diabetes, regardless of diabetes duration. No significant interaction was observed between diabetes duration and treatment in the analysis of both trials.
DIABETES OBESITY & METABOLISM
(2021)
Article
Medicine, General & Internal
Harpreet S. Bajaj, Jens Aberle, Melanie Davies, Anders Meller Donatsky, Marie Frederiksen, Dilek G. Yavuz, Amoolya Gowda, Ildiko Lingvay, Bruce Bode
Summary: This study compared the effectiveness and safety of icodec titrated with a dosing guide app to once-daily basal insulin analogues in treating patients with type 2 diabetes. The results showed that icodec with app was more effective in reducing HbA1c levels, improving treatment satisfaction and compliance, with similar rates of hypoglycemia compared to OD analogues.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Multidisciplinary Sciences
Hsuan-Chih Chen, Chen-Yu Wang, Hsiu-Hsi Chen, Horng- Huei Liou
Summary: This study investigates the cost-effectiveness of adding exenatide to conventional pharmacotherapy for patients with Parkinson's disease and diabetes mellitus. The results show that adding exenatide brings clinical benefits and is cost-effective in treating patients with Parkinson's disease and diabetes mellitus.
Article
Endocrinology & Metabolism
Alex Ramirez-Rincon, Carlos E. Builes-Montano, Jaime A. Hincapie-Garcia, Victor M. Blanco, Jose F. Botero-Arango
Summary: This real-life study found that IDegLira was effective in glycemic control for patients with type 2 diabetes who did not respond to other treatments, and it had an adequate safety profile.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
Ronald M. Goldenberg, Vanita R. Aroda, Liana K. Billings, A. Sia Louise Christiansen, Anders Meller Donatsky, Ehsan Parvaresh Rizi, Gracjan Podgorski, Katarina Raslova, David C. Klonoff, Richard M. Bergenstal
Summary: This study compared the use of insulin degludec and glargine U100 in patients with type 2 diabetes, showing that degludec performed better in terms of TIR and time in tight glycaemic range.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Jochen Seufert, Peter Wiesli, Andreas Fritsche, Helmut Anderten, Katrin Pegelow, Stefan Pscherer, Martin Pfohl
Summary: This study evaluated the effectiveness and safety of switching basal insulin in a BI-supported oral therapy to insulin glargine 300 U/ml in adults with inadequately controlled type 2 diabetes. The results showed that switching to Gla-300 improved metabolic control and treatment satisfaction within 12 months in clinical practice, with decreased risk of symptomatic and nocturnal hypoglycemia and without weight gain.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Jeff Unger, Dale C. Allison, Margit Kaltoft, Kavitha Lakkole, Jayant K. Panda, Chethana Ramesh, Mehmet Sargin, Elena Smolyarchuk, Melissa Twine, Benjamin Wolthers, Gizem Yarimbas, Marouan Zoghbi
Summary: The study compared the efficacy of liraglutide versus oral antidiabetic drugs in maintaining glycemic control in patients with uncontrolled type 2 diabetes, and found that liraglutide was more effective in controlling blood sugar levels over a longer period and had better outcomes in terms of HbA1c and body weight compared to OADs.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Faisal Al Malki, Bandar El Damanhoury, Abdallah Othman, Zain Alghamdi, Majed AlQahtani, Amr Madgy, Zahir Chouikrat
Summary: This study evaluated the effectiveness and safety of switching to insulin glargine 300 U/mL (Gla-U300) in patients with uncontrolled type 2 diabetes (T2D) in Saudi Arabia. The results showed a significant reduction in HbA1c levels and an increased percentage of patients achieving the predefined individualized HbA1c goal after switching to Gla-U300.
DIABETES OBESITY & METABOLISM
(2023)
Article
Medicine, Research & Experimental
Omar Dabbous, Benit Maru, Jeroen P. Jansen, Maria Lorenzi, Martin Cloutier, Annie Guerin, Irina Pivneva, Eric Q. Wu, Ramesh Arjunji, Douglas Feltner, Douglas M. Sproule
ADVANCES IN THERAPY
(2019)
Article
Economics
Devin Incerti, Jeffrey R. Curtis, Jason Shafrin, Darius N. Lakdawalla, Jeroen P. Jansen
Article
Mathematical & Computational Biology
Joy Leahy, Howard Thom, Jeroen P. Jansen, Emma Gray, Aisling O'Leary, Arthur White, Cathal Walsh
STATISTICS IN MEDICINE
(2019)
Article
Economics
Devin Incerti, Howard Thom, Gianluca Baio, Jeroen P. Jansen
Article
Economics
Asa Ericsson, Adam Fridhammar
JOURNAL OF MEDICAL ECONOMICS
(2019)
Article
Health Care Sciences & Services
Jeroen P. Jansen, Devin Incerti, Jeffrey R. Curtis
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
(2019)
Article
Clinical Neurology
Kenneth Berger, Steve Kanters, Jeroen P. Jansen, Andrew Stewart, Susan Sparks, Kristina An Haack, Anna Bolzani, Gaye Siliman, Alaa Hamed
JOURNAL OF NEUROLOGY
(2019)
Letter
Medicine, Research & Experimental
Omar Dabbous, Benit Maru, Jeroen P. Jansen, Maria Lorenzi, Martin Cloutier, Annie Guerin, Irina Pivneva, Eric Q. Wu, Ramesh Arjunji, Douglas Feltner, Douglas M. Sproule
ADVANCES IN THERAPY
(2019)
Article
Economics
Jeroen P. Jansen, Devin Incerti, Mark T. Linthicum
Article
Surgery
Jesse Sussell, Alison R. Silverstein, Prodyumna Goutam, Devin Incerti, Rebecca Kee, Corinna X. Chen, Donald S. Batty, Jeroen P. Jansen, Bertram L. Kasiske
AMERICAN JOURNAL OF TRANSPLANTATION
(2020)
Article
Mathematical & Computational Biology
Shannon Cope, Keith Chan, Jeroen P. Jansen
RESEARCH SYNTHESIS METHODS
(2020)
Article
Economics
Michael Willis, Adam Fridhammar, Jens Gundgaard, Andreas Nilsson, Pierre Johansen
Article
Economics
Shannon Cope, Kabirraaj Toor, Evan Popoff, Rafael Fonseca, Ola Landgren, Maria-Victoria Mateos, Katja Weisel, Jeroen Paul Jansen
Article
Oncology
Ida Skarping, Kristoffer Nilsson, Looket Dihge, Adam Fridhammar, Mattias Ohlsson, Linnea Huss, Par-Ola Bendahl, Katarina Steen Carlsson, Lisa Ryden
Summary: Implementing the NILS model in predicting nodal status for breast cancer patients can reduce the proportion of low-risk patients undergoing SLNB, leading to cost reductions and overall health gains.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Economics
Adam Fridhammar, Ulrika Axelsson, Ulf Persson, Anders Bjartell, Carl A. K. Borrebaeck
Summary: The study aimed to investigate the health-economic value of introducing a new and more accurate blood-based diagnostic test for prostate cancer. Results showed that the new test has the potential to reduce the number of biopsies needed, lower healthcare costs, and improve patient care in the Swedish region of Skane.
PHARMACOECONOMICS-OPEN
(2021)